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Abstract
Background: Recent studies have reported elevated prostaglandin levels in patients with renal artery stenosis and 
hypertension. To investigate whether a distinction between essential hypertension and hypertension with renal artery 
stenosis is possible by measuring eicosanoid excretion, we studied the excretion of these compounds in patients with 
essential hypertension and in hypertensives with concomitant renal artery stenosis.
Methods: The 24-h urinary excretion of metabolites of prostaglandin I 2, prostaglandin E 2 and metabolites of 
thromboxane A 2 was sampled under standardised conditions, in 15 patients with essential hypertension and in 15 
patients with unilateral renal artery stenosis with hypertension. Also clinical and biochemical characteristics of the 
subjects were analysed.
Results: The patients with renal artery stenosis had significantly lower excretion of prostaglandin I2 than did the 
essential hypertensive patients. However, the overlap in the values was large, thus not allowing a diagnostic 
differentiation according to urinary prostaglandin I2 levels. The excretion of prostaglandin E 2 and of metabolites of 
thromboxane A 2 showed no significant differences among the groups.
Conclusions: Measurement of urinary prostaglandin or prostaglandin metabolite excretion did not contribute to 
the non-invasive detection of the presence of a renal artery stenosis in the patients in this study.
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1. Introduction
Prostaglandin endoperoxides are constituents 
of the renal regulatory mechanism of angioten­
* Corresponding author. Tel. (080) 614782; Fax (080) 
541734.
sin-induced hypertension, both in the animal 
model and in humans [1-4]. In animal studies it 
was shown th a t in ren in-angio tensin-dependent 
hypertension the levels of plasma 6-ketopros- 
taglandin F la> a stable m etabolite of prostaglandin
I 2 (P G I2), and thromboxane B 2 (PG B 2), a stable 
metabolite of thromboxane A 2 (P G A 2), are ele­
vated and that also urinary excretion of 6-keto-
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prostaglandin F lttr and PGB2 is increased [2]. 
Recent studies in humans have revealed that in 
subjects with renal artery stenosis, systemic 
plasma levels of prostaglandin E 2 (PG E 2) are 
higher than in patients with essential hyperten­
sion and that the renal vein plasma levels of 
P G E 2 are higher on the stenotic side than on the 
non-stenotic side [3,4]. Also levels of P G I2 and of 
P G A 2 were shown to be elevated in renal artery 
stenosis in humans [5-9].
The prostaglandins have a predominantly va­
sodilator effect at the level of the afferent 
glomerular arteriole [10,11]- The intrarenal ef­
fects of the renin-angiotensin  system are mainly 
confined to the efferent arteriole and exert a 
vasoconstrictor effect through angiotensin II, 
whose effects are partly mediated via the vaso­
constrictive activity of P G A 2 [1,10]. These micro- 
circulatory changes act to preserve glomerular 
filtration fraction in states of impaired renal per­
fusion pressure [8,13]. If renal perfusion pressure 
declines, P G I2 production in the endothelial cells 
of the vas afferens rises [7], The P G I2 in turn 
potentiates renin release by the juxtaglomerular 
apparatus [12,14].
Recent experiments have confirmed the im­
portance of the mechanisms described in renal 
artery stenosis (RAS) in humans [3,4,8,15,16]. In ­
travenous aspirin lowered P G E 2 and renin con­
centrations, in the human renal vein from the 
kidney distal to an unilateral RAS, with concomi­
tant lowering of the blood pressure [3]. A  signifi­
cant decline in P G E 2 and renin concentrations, 
after the administration of aspirin, was also re ­
ported in the renal veins distal to a unilateral 
RAS, in patients in whom blood pressure was 
cured or improved after percutaneous translumi­
nal renal angioplasty, but not in patients in whom 
blood pressure did not improve after the relief of 
a renal artery stenosis [4], Thus, by inhibiting 
P G E 2 production, renin production was attenu­
ated and blood pressure fell, at least in the acute 
experiments [3,4].
On the basis of these experiments it can be 
assumed that in renovascular hypertension the 
renal production of P G E 2, P G I2 and P G A 2 is 
increased [2-4]. In essential hypertension the 
eicosanoids do not seem to participate directly in
the control of arterial pressure and their levels 
have not been shown to be raised [8,17]. Thus, by 
measuring renal prostaglandin production it might 
be possible to differentiate between essential hy­
pertension and hypertension with a unilateral
RAS.
The least invasive and most reliable way of 
assessing intrarenal prostaglandin production is 
to measure the urinary excretion of P G E 2, 6-ke- 
toprostaglandin F la, and PGB2 [18]. Only a slight 
day-to-day variation in the excretion of P G E 2 has 
been reported [19]. We measured the 24-h uri­
nary excretion of these eicosanoids in patients 
with essential hypertension and in patients with 
unilateral renal artery stenosis and hypertension, 
to examine whether the assumed differences in 
urinary prostaglandin excretion would be appar­
ent.
2. Patients and methods
Included in the study were 15 patients with 
essential hypertension and 15 patients with hy­
pertension and a unilateral renal artery stenosis. 
Hypertension was defined as a supine blood pres­
sure, taken on 3 different occasions, above 90 
mmHg diastolic on each occasion. The diagnosis 
of essential hypertension was made if laboratory 
investigation and angiography had excluded sec­
ondary forms of hypertension. Subjects with pro­
teinuria over 1.5 g a day, haematuria or abnor­
malities on urine microscopy were excluded. Sub­
jects with diabetes mellitus were also excluded 
from the study. The diagnosis of unilateral renal 
artery stenosis was made if on a Seldinger arteri­
ography or on an arterial digital subtraction an­
giography a luminal narrowing of more than 70% 
of the surface was present. Fifteen successive 
patients were selected in whom a diagnosis of 
renal artery stenosis was made. The patients were 
included if their characteristics were in agree­
ment with the protocol as outlined above. The 
subjects with essential hypertension were also 15 
successive patients in whom the diagnosis of es­
sential hypertension was made and whose clinical 
data matched the study terms. In all subjects
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antihypertensive medication >and a sodium-re­
stricted diet were discontinued at least 2 weeks 
before the urine sampling. In the setting of the 
outpatient department it is hardly possible to 
bring subjects into a fixed sodium balance. We 
assumed that by taking an unlimited sodium diet 
the patients would reach a steady state with re­
gard to their salt status. All other medication was 
also withheld. Special emphasis was given to pre­
vent the use of cyclo-oxygenase-inhibiting drugs. 
The patients were asked to refrain from smoking 
and sexual activity from 24 h before the start of 
the urine sampling.
Urine was sampled during two successive peri­
ods of 24 h because, in case of any collection 
problem, there would be a second sample. As 
standard the first of the two samples was used. In
2 cases the ratio of P G E 2 and prostaglandin F2cc, 
which for this purpose was also measured, was 
over 0.5, indicating that the sample was contami­
nated by seminal fluid and therefore the second 
sample was used [19]. The creatinine content of 
the urine sample that was used for the study was 
measured to calculate the endogenous creatinine 
clearance (ECC). Twenty-four hour urinary 
sodium content was measured in the same 24-h 
urine as the prostaglandins or, if this was not 
feasible, it was measured in a 24-h urine sample 
of the same week in which the 24-h urine for the 
prostaglandin measurements was taken.
The levels of P G E 2, PG F2a, 6-keto-PGFla and 
TxB2 were determined by radioimmunoassays, 
according to procedures described previously 
[20,21]. After 10 consecutive assays the P G E 2 
determinations showed 6.4 and 15%, the PGF2or 
assay 5.3 and 11%, the 6-keto-PGFla assay 7.3 
and 9.6%, and the TxB2 assay 8.1 and 12.5% 
intra- and interassay variability, respectively.
To relate prostaglandin excretion to functional 
renal mass, 24-h urinary prostaglandin metabolite 
excretion was indexed to the 24-h creatinine con­
tent of the same sample. Plasma renin activity 
(PRA) was measured under baseline conditions, 
meaning that all antihypertensive medications 
were stopped for at least 2 weeks. After blood for 
baseline PRA  was taken, patients took an oral 
dose of 25 mg of captopril and 60 min after that 
blood for captopril-stimulated PRA  was drawn.
During this procedure the patients rem ained in 
the supine position.
The features of gender, age, body mass index 
(body weight in kilograms divided by the square 
of the length in metres), endogenous creatinine 
clearance, PRA, 24-h urinary sodium content, 
smoking habits and blood pressure levels were 
compared as were the 24-h urinary P G E 2, 6-keto- 
PG Fla and thromboxane B 2 excretion and the 
prostaglandin levels indexed to 24-h creatinine.
Statistical analysis
Patient characteristics among the groups were 
compared with Wilcoxon’s rank sum test apart 
from the gender and the num bers of smokers, 
who were compared with Fisher's exact test. The 
24-h urinary prostaglandin and prostaglandin 
metabolite excretion w ere also compared by 
Wilcoxon’s rank sum test. Outcomes with a p-  
value of less than 5% w ere regarded as signifi­
cant. All tests were perform ed two-sided. In a 
forward stepwise logistic regression procedure the 
independent relation of age, ECC, body mass 
index, smoking, systolic and diastolic blood pres­
sure and the diagnosis of essential hypertension 
and renal artery stenosis to the prostaglandin and
Table 1
Clinical characteristics of patients with essential hypertension 
(EH) (n —15) and patients with renal artery stenosis (RAS)
(n —15)
EH RAS
Gender (F/M ) 5/10 3/12
Age (yrs) 45 (20-63) 53 (21-74)
Body mass index (kg/m 2) 25 (21-33) 25 (21-31)
Urinary Na (mmol/24 h) 155 (40-313) 154 (40-200)
ECC (ml/min) 94 (64-141) 82 (29-124)
No. of smokers (%) 1 (6%)  * * 9 (60%)
Systolic blood pressure 170 (140-240) 184 (144-220)
(mmHg)
Diastolic blood pressure 108 (80-150) 110(80-130)
(mmHg) —
Median and (between brackets) the range are indicated, un­
less indicated otherwise. ECC = endogenous creatinine clear­
ance. * * Indicates significant difference between EH and
RAS, p  < 0.01.
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Table 2
Urinary prostaglandin metabolite excretion and plasma renin activity in essential hypertensives (EH) (n = 15) and patients with
hypertension and renal artery stenosis RAS (n = 15)
EH RAS
6-KetoprostagIandin Fla (nmol/24 h) 
Prostaglandin E 2 (nmol/24 h) 







Prostaglandin metabolite excretion ( n m o l / I / 2 4  h) indexed to urinary creatinine excretion ( m m o l / I / 24 h) 
6-Ketoprostaglandin F ia 0.13(0.07-0.28) * 0.08(0.04-0.27) 
Prostaglandin E 2 0.05 (0.01-1.02) 0.06 (0.02—0.45) 
Thromboxane B? 0.08 (0.04-0.21) 0.12 (0.03—0.36)
4*
Plasma renin activity ( n m o l / I / h )  
Baseline





Given are Medians and between brackets ranges. * ’ Indicates difference p < 0.01; * indicates difference p  < 0.05.
prostaglandin metabolite excretion were anal­
ysed.
3. Results
The study included 15 patients with essential 
hypertension and 15 with unilateral RAS. All 
patients with RAS had atherosclerotic vascular 
narrowing as evidenced by angiography.
The num ber of smokers was significantly higher 
in the patients with RAS (Table 1). The clinical 
features of gender, age and body mass index were 
not significantly different among the groups (Ta­
ble 1). Twenty-four hour urinary sodium excre­
tion was also not significantly different: median 
155 (range 40-313) m m ol/24  h in the E H  group 
and 154 (40-200) m m ol/24  h in the group with 
RAS (Table 1). Blood pressure in the essential 
hypertensives and in those with RAS was not 
significantly different: 170 (140-240)/108 (80- 
150) and 184 (144-220)/110 (80-130) mmHg, 
respectively (Table 1). Baseline PRA was 0.87 
(0.1-3.96) n m o l / l / h  in the E H  group and 1.9 
(0.4-7.7) n m o l / l / h  in the RAS group, which was 
not significantly different (Table 2). The capto- 
pril-stimulated PR A  was significantly higher in 
the patients with RAS: 9.8 (0.1-51.1) vs. 1.24 
(0.1-2.89) n m o l / l / h  in the E H  group (Table 2). 
In the group of essential hypertensives there was 
no significant rise in PR A  after captopril, but in
the patients with a RAS the rise in PRA  after 
captopril was significant (Table 2). Twenty-four 
hours 6-keto-prostaglandin F la excretion was with 
a median of 1.1 (0.28-2.5) nm ol/24 h signifi­
cantly lower in the patients with RAS as com­
pared with the value of 1.9 (0.54-3.6) nm ol/24  h 
in the essential hypertensives (Table 2). Also in­
dexed to the 24-h creatinine excretion, 24-h 6-ke- 
toprostaglandin Fla excretion was significantly 
lower in the patients with RAS; 0.08 (0.04-0.28) 
vs. 0.13 (0.07-0.27) nmol/mmol (Table 2). R e­
garding the other prostaglandins and prostaglan­
din metabolites, no significant differences in the 
values for the 24-h urinary excretion among the 
groups were detected.
In the forward stepwise logistic procedure the 
diagnosis of renal artery stenosis slfowed a signifi­
cant relationship to the 24-h 6-ketoprostaglandin 
Fla urinary excretion ( r 2 =  0.30, p  < 0.01). Fur­
thermore, PGB2 excretion showed a significant 
relation to smoking ( r 2 =  0.22, p  <  0.01).
%
4. Discussion
Because renovascular hypertension can be 
treated successfully in a large number of patients, 
it is worthwhile to try to identify those with this 
condition among the general hypertensive popu­
lation [22-25]. However, the certain diagnosis of 
a renal artery stenosis can only be made by an­
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giography [22-25]. In view of the low prevalence 
of renal artery stenosis in the hypertensive popu­
lation, angiography, because of its invasive nature 
and cost, cannot be used as a screening proce­
dure. Therefore a sensitive and reliable non-inva- 
sive screening procedure that can detect this con­
dition would be an important tool in clinical 
practice.
A  number of studies have shown that in the 
case of stimulation of the renin-angiotensin sys­
tem, especially as a result of renal ischaemia, 
renal eicosanoid production rises [1-9], Since a 
significant renal artery stenosis is a situation of 
renal ischaemia, it might be expected that this 
condition results in an elevated renal prostaglan­
din production. Thus, by assessing renal 
eicosanoid production, which can be done reli­
ably and non-invasively by measuring urinary 
prostaglandin and prostaglandin metabolite ex­
cretion, the presence of a renal artery stenosis 
should be detectable if the concomitant hyperten­
sion is related to the stenosis and therefore 
renin-angiotensin-mediated.
The patients with a RAS in the present study 
showed a significant rise in PRA  after the admin­
istration of captopril, indicating the renin depen­
dency of their renal haemodynamic regulation, as 
compared with the absence of such a rise in the 
essential hypertensive patients.
However, the expected higher levels of urinary 
prostaglandin excretion were not present in the 
group with RAS. On the contrary, we found a 
significantly lower 6-keto-prostaglandin Fla ex­
cretion in the patients with a unilateral RAS.
How can these results be explained? One dif­
ference between the groups is the number of 
smokers, which was higher in the patients with 
RAS. To exclude as much as possible the acute 
effects of smoking, the participants were asked to 
refrain from smoking for at least 24 h. Most of 
the clinical studies concerning eicosanoid produc­
tion do not mention smoking habits of the stud­
ied population and in one study smoking discon­
tinuation of 3 h was considered long enough to 
minimize its effects on eicosanoid levels [26]. Cre­
ating a group of non-smoking patients with RAS 
would have introduced considerable bias, as 
atherosclerotic renal artery disease is strongly
linked to smoking. Smoking causes a rise in 
platelet-derived prostaglandin production, mainly 
of T x A 2 and, probably vessel-wall-derived, 
prostaglandin I 2 as m easured by the elevated 
urinary excretion of their metabolites TxB2 and 
6-ketoprostagIandin Fla [27,28]. We could not 
substantiate such a rise because the  levels of 
TxB2 were comparable in the two groups, al­
though TxB2 excretion showed a relation to 
smoking. The level of P G I2 was lower in the 
group of RAS with the highest num ber of smok­
ers. Because smoking would have enhanced the 
differences expected, it seems very unlikely that 
the difference in smoking could have substantially 
influenced the results of prostaglandin I 2 and of 
6-ketoprostaglandin Fla excretion. A part from 
TxB2, the other prostanoid excretions also did 
not show a relation to smoking.
O ther causes of diminished 6-ketoprostaglan­
din F la excretion might be found in a difference 
in functional renal mass or the presence of 
parenchymal renal disease. A severely diminished 
renal mass can cause a decline in renal 
prostaglandin production because renal tissue 
produces the renal prostanoids. Renal parenchy­
mal diseases can give rise to various changes in 
renal prostaglandin production including an in­
crease or decrease of the excretion depending on 
the offending condition [29-32]. However, be­
tween the two groups the  endogenous creatinine 
clearance was not statistically different, indicating 
a comparable renal functional mass, and also the 
eicosanoid excretion indexed to creatinine excre­
tion showed a lower 6-ketoprostaglandin F la ex­
cretion in the patients with a RAS, which makes 
a diminished functional renal mass unlikely as the 
cause of the different findings. As we excluded 
patients with parenchymal renal disease, the dif­
ference in eicosanoid excretion can also not be 
explained by possible renal diseases.
W hat o ther explanation for the results of the 
present study might be valid? In a recent study of 
renal vein prostaglandin concentrations before 
and after cyclo-oxygenase inhibition with aspirin 
DL-lysine it was found  th a t the  level of 
prostaglandins in the veins of the stenotic kidney 
was increased in relation to the  o ther kidney and 
declined within 30 mins after intravenous aspirin
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DL-lysine [3,4]. Although the level of the 
prostaglandins in the aorta was also higher than 
in patients with essential hypertension and low 
renin, they were not lower than in essential hy­
pertensive patients with high renin, and as renal 
flow was not measured it remains unclear if renal 
prostaglandin production was in fact increased. If 
the concentration changes were caused by changes 
in flow, it is clear that such changes cannot be 
detected by differences in 24-hour urinary 
eicosanoid excretion.
As there were no significant differences in 
baseline PRA between our patients with essential 
hypertension and those with RAS, it might well 
be that the only differences present in such pa­
tients are differences in prostaglandin concentra­
tions between the affected and non-affected renal 
veins.
To elucidate this problem, both hormone con­
centrations and renal blood flow have to be stud­
ied. Probably then an explanation can be given 
for the absence of the expected differences in 
prostaglandin excretion in the present study.
Due to the overlap in individual values, 6-keto- 
prostaglandin F la excretion could also not be 
used to make a diagnostic differentiation between 
the subjects. Thus, by measuring the concentra­
tions of renal prostaglandin or prostaglandin 
metabolites in the urine, no distinction could be 
made between essential hypertension and hyper­
tension with renal artery stenosis.
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